INOVIQ Defines EXO-OC Commercialisation Path after Independent Review

INOVIQ ASX:IIQ has mapped a 12-to-18-month pathway to commercialise its EXO-OC ovarian cancer test as a US laboratory developed test (LDT), after an independent technical review supported its assessment of why the OC2200 verification study could not be completed.The review confirmed that difference…